| Quarterly Financials | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 9 | 6 | 8 | 10 | 9 | 9 | 10 | 7 | 21 | 14 | 16 | 12 | 36 | 25 |
| Expenses | 7 | 5 | 6 | 7 | 7 | 7 | 8 | 6 | 17 | 11 | 11 | 8 | 26 | 18 |
| EBITDA | 2 | 1 | 2 | 2 | 3 | 2 | 3 | 2 | 4 | 4 | 5 | 5 | 10 | 7 |
| Operating Profit % | 20 % | 14 % | 18 % | 21 % | 23 % | 20 % | 22 % | 20 % | 12 % | 19 % | 26 % | 34 % | 25 % | 22 % |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 1 |
| Profit Before Tax | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 3 | 3 | 4 | 4 | 6 | 4 |
| Tax | -1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 |
| Net Profit | 3 | 1 | 1 | 2 | 2 | 1 | 2 | 1 | 2 | 2 | 3 | 3 | 6 | 3 |
| EPS in ₹ | 15.02 | 0.88 | 1.15 | 1.77 | 1.72 | 1.22 | 1.48 | 0.94 | 1.41 | 1.99 | 2.69 | 2.42 | 6.15 | 2.66 |
Trident Lifeline
Trident Lifeline
304.00
+44.85
(17.31%)
Company has added their latest Presentation1 day ago
Show All
Market Cap
298.00 Cr
EPS
10.22
PE Ratio
21.19
Dividend Yield
0.00 %
Industry
Healthcare52 Week High
339.00
52 Week Low
222.00
PB Ratio
5.27
Debt to Equity
0.26
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Company News
View All News
Trident Lifeline Limited reported quarterly revenue of ₹1,935.48 lakh, marking 27% year-over-year growth. The pharmaceutical company's EBITDA increased 20% to ₹546.36 lakh with margins at 28%. Profit after tax grew 15% to ₹347.59 lakh, while earnings per share reached ₹3.02. The company operates across 43 countries with 1,035 export market products registered and 2,329 registrations in process. Trident maintains a hybrid manufacturing model combining own facilities and contract manufacturing, with presence in African, Latin American, CIS and East Asian markets. The company's product portfolio spans 3,364 products across multiple therapeutic categories including tablets, capsules, syrups and ointments.
Trident Lifeline Limited's Board of Directors approved un-audited standalone and consolidated financial results for the quarter ended June 30, 2025. The company reported standalone net sales of Rs 2,084.65 lacs and net profit of Rs 347.59 lacs for the quarter. On a consolidated basis, net sales were Rs 3,401.07 lacs with net profit of Rs 306.28 lacs. The Board also appointed M/s. Amareliya & Associates as Secretarial Auditor for a five-year term from FY 2025-26 to FY 2029-30, subject to shareholder approval. The company operates as a holding company with stakes in multiple subsidiaries including TNS Pharma Pvt. Ltd., TLL Parenterals Ltd., TLL Elements Private Ltd., Trident Mediquip Ltd., and TLL Herbal Ltd. No investor complaints were pending during the quarter.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,706.70 | #1 4,15,996.70 | 35.67 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 54.49 | |
6,595.50 | 1,76,536.60 | 80.00 | 9,712.00 | 0.89 | 2,191 | 23.05 | 42.76 | |
3,741.90 | 1,26,260.50 | 62.71 | 11,539.40 | 6.99 | 1,911 | 19.91 | 74.62 | |
1,554.60 | 1,25,954.00 | 23.28 | 28,409.50 | 7.12 | 5,291 | 9.88 | 63.54 | |
1,270.30 | 1,07,834.90 | #1 18.67 | 33,741.20 | 16.73 | 5,725 | 1.26 | 47.76 | |
2,567.20 | 1,06,298.30 | 61.04 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 54.82 | |
969.80 | 1,00,135.40 | 21.00 | 23,511.00 | 13.82 | 4,615 | -0.19 | 48.14 | |
1,929.10 | 90,635.80 | 27.13 | 22,909.50 | 19.94 | 3,306 | #1 112.49 | 46.32 | |
34,405.00 | 74,786.90 | 51.70 | 6,684.70 | 10.80 | 1,414 | 27.83 | 53.98 | |
1,139.80 | 67,256.80 | 19.18 | 31,378.10 | 17.55 | 3,366 | -0.50 | 50.23 |
Forecast
Actual
Growth Rate
Revenue Growth
41.95 %
Net Income Growth
-1.67 %
Cash Flow Change
111.74 %
ROE
-13.85 %
ROCE
0.80 %
EBITDA Margin (Avg.)
-2.53 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 14 | 63 | 87 | 156 |
| Fixed Assets | 1 | 3 | 21 | 45 |
| Current Assets | 11 | 49 | 52 | 90 |
| Capital Work in Progress | 0 | 5 | 4 | 2 |
| Investments | 0 | 0 | 0 | 28 |
| Other Assets | 12 | 55 | 62 | 0 |
| Total Liabilities | 14 | 63 | 87 | 156 |
| Current Liabilities | 8 | 12 | 20 | 54 |
| Non Current Liabilities | 2 | 4 | 13 | 33 |
| Total Equity | 5 | 47 | 54 | 65 |
| Reserve & Surplus | -3 | 34 | 40 | 53 |
| Share Capital | 8 | 12 | 12 | 12 |
Cash Flow
| Cash Flow | 2022 | 2023 | 2024 |
| Net Cash Flow | 0 | 14 | -7 |
| Investing Activities | -0 | -10 | -20 |
| Operating Activities | -0 | -19 | 2 |
| Financing Activities | 1 | 42 | 11 |
Share Holding
| % Holding | Aug 2022 | Sept 2022 | Oct 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 100.00 % | 69.57 % | 69.57 % | 69.85 % | 69.99 % | 70.04 % | 70.04 % | 70.04 % | 67.48 % | 65.51 % | 62.99 % | 62.99 % | 63.04 % | 63.04 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 4.64 % | 6.02 % | 6.02 % | 6.09 % | 6.09 % | 6.62 % | 7.21 % |
| DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.09 % | 0.39 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 23.18 % | 23.18 % | 15.13 % | 13.38 % | 14.30 % | 14.82 % | 14.43 % | 16.39 % | 18.37 % | 19.40 % | 18.90 % | 18.26 % | 17.90 % |
| Others | 0.00 % | 7.25 % | 7.25 % | 15.02 % | 16.63 % | 15.66 % | 15.14 % | 10.88 % | 10.10 % | 10.10 % | 11.52 % | 12.02 % | 11.99 % | 11.45 % |
| No of Share Holders | 0 | 10 | 1,389 | 397 | 388 | 387 | 439 | 481 | 500 | 502 | 507 | 523 | 534 | 549 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 28 Jul 2025 |  Quarterly Result Announcement | NA | 28 Jul 2025 | 270.00 | 273.20 |
| 09 May 2025 |  Extraordinary General Meeting | NA | 09 May 2025 | 252.65 | 287.00 |
| 28 Apr 2025 | Quarterly Result Announcement | NA | 28 Apr 2025 | 270.00 | 284.00 |
| 22 Jan 2025 | Quarterly Result Announcement | NA | 22 Jan 2025 | 266.00 | 281.50 |
| 19 Oct 2024 | Quarterly Result Announcement | NA | 19 Oct 2024 | 284.95 | 299.00 |
| 20 Sept 2024 |  Annual General Meeting | NA | 20 Sept 2024 | 266.00 | 314.00 |
Announcements
Announcement under Regulation 30 (LODR)-Investor Presentation
1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication1 day ago
1 day agoStatement Of Deviation For The Quarter Ended June 3020253 days ago
3 days agoAppointment Of Secretarial Auditor Of The Company For The First Term From Financial Year 2025-26 To FY 2029-30 Subject To Approval Of The Members In Ensuing AGM3 days ago
3 days agoFinancial Result For The Quarter Ended June 20253 days ago
3 days agoBoard Meeting Outcome for For Financial Result For Quarter Ended June 30 20253 days ago
3 days agoBoard Meeting Outcome for For Financial Result For Quarter Ended June 30 20253 days ago
3 days agoBoard Meeting Intimation for Consideration Of Un-Audited Financial Results For The Quarter Ended June 30 20259 days ago
9 days agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 09, 2025
Jul 09, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 04, 2025
Jul 04, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 04, 2025
Jul 04, 2025Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeover) Regulations 2011Jul 03, 2025
Jul 03, 2025Announcement under Regulation 30 (LODR)-AllotmentJul 01, 2025
Jul 01, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On Today I.E. On July 01 2025 In Terms Of Second Proviso To Regulation 30(6) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 01, 2025
Jul 01, 2025Closure of Trading WindowJun 28, 2025
Jun 28, 2025Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeover) Regulations 2011Jun 12, 2025
Jun 12, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 12, 2025
Jun 12, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 12, 2025
Jun 12, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 12, 2025
Jun 12, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 12, 2025
Jun 12, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 12, 2025
Jun 12, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 12, 2025
Jun 12, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 12, 2025
Jun 12, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 12, 2025
Jun 12, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 12, 2025
Jun 12, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 12, 2025
Jun 12, 2025Announcement under Regulation 30 (LODR)-AllotmentJun 09, 2025
Jun 09, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On Today I.E. On June 09 2025 In Terms Of Second Proviso To Regulation 30(6) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jun 09, 2025
Jun 09, 2025Announcement Under Regulation 30- Cessation Of Corporate OfficeMay 19, 2025
May 19, 2025Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015 -Launch Of New Skin Care Brand YES By Subsidiary Company- TLL Elements Private LimitedMay 12, 2025
May 12, 2025Scrutinizer"S ReportMay 12, 2025
May 12, 2025Shareholder Meeting / Postal Ballot-Outcome of EGMMay 09, 2025
May 09, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 30, 2025
Apr 30, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 29, 2025
Apr 29, 2025Non-Applicability Of Regulation 23(9) Of SEBI (Listing Obligation & Disclosures Requirements) Regulation 2015 For March 31 2025Apr 28, 2025
Apr 28, 2025Integrated Filing (Financial)Apr 28, 2025
Apr 28, 2025Statement Of Deviation Or Variation Of Funds Under Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements)
Regulations 2015Apr 28, 2025
Apr 28, 2025Appointment Of Internal AuditorApr 28, 2025
Apr 28, 2025Result-Financial Result For The Half Year And Year Ended On March 31 2025Apr 28, 2025
Apr 28, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On 28 April 2025Apr 28, 2025
Apr 28, 2025Board Meeting Intimation for Approval Of Audited Standalone And Consolidated Financial Results For The Half Year And Year Ended 31St March 2025Apr 22, 2025
Apr 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 18, 2025
Apr 18, 2025Shareholders Meeting-EGM-09-05-2025Apr 17, 2025
Apr 17, 2025Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 17, 2025
Apr 17, 2025Announcement under Regulation 30 (LODR)-Issue of SecuritiesApr 16, 2025
Apr 16, 2025Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationApr 16, 2025
Apr 16, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On Today I.E. 16.04.2025Apr 16, 2025
Apr 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 11, 2025
Apr 11, 2025Board Meeting Intimation for Consider And Approve The Proposal To Raise Funds At The Board Meeting To Be Held On April 16 2025Apr 09, 2025
Apr 09, 2025Closure of Trading WindowMar 31, 2025
Mar 31, 2025Technical Indicators
RSI(14)
Neutral 61.44
ATR(14)
Volatile 13.36
STOCH(9,6)
Neutral 49.05
STOCH RSI(14)
Neutral 46.71
MACD(12,26)
Bullish 2.12
ADX(14)
Weak Trend 9.25
UO(9)
Bearish 55.62
ROC(12)
Uptrend And Accelerating 14.63
WillR(14)
Overbought 0.00
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
